Literature DB >> 23260343

Synovial sarcomas of the head and neck: comparative analysis with synovial sarcoma of the extremities.

Rosa Angélica Salcedo-Hernández1, Leonardo Saúl Lino-Silva, Kuauhyama Luna-Ortiz.   

Abstract

OBJECTIVE: This study analyzed synovial sarcoma (SS) of the head and neck in order to identify features associated with survival improvement and compared them with the survival of SS of limbs.
METHODS: Clinical charts and histopathologic material with analysis for SYT/SSX gene rearrangement of 16 patients were reviewed. The clinicopathologic features and their association with survival were analyzed and compared with 174 SS of limbs.
RESULTS: The average age was 24.2 years (range 21-86). Eight cases occurred in each sex. The most frequent site was the parapharyngeal space (PPS). The mean tumor size was 5.38cm. Sixty-nine percent occurred in Stages II-III and 9% in Stage IV. Fifteen cases were excised: R0 resection in seven (46.7%) cases and R1 resection in eight (53.3%) cases. No patient with R0 resection has recurred, and three patients (37.5%) with R1 resection have recurred (p=0.035). Patients with R0 surgery had better survival rates compared to those who received other treatments (p=0.045). SS of head and neck showed a 5-year survival rate of 58% compared to 44.6% of the limbs (p=0.450).
CONCLUSION: The most prevalent location was the PPS. Surgical resection with clear margins correlated with low recurrence. Head and neck sarcomas had similar survival rates compared to sarcomas of limbs.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23260343     DOI: 10.1016/j.anl.2012.11.015

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  7 in total

1.  Factors Associated With Survival in Patients With Synovial Cell Sarcoma of the Head and Neck: An Analysis of 167 Cases Using the SEER (Surveillance, Epidemiology, and End Results) Database.

Authors:  Jon Mallen-St Clair; Armin Arshi; Elliot Abemayor; Maie St John
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

2.  A case of a 22-year-old man with primary synovial sarcoma of the parapharyngeal space with an AR somatic mutation: A case report and review of the literature.

Authors:  He Jiang; Ge Ma; Zunzhen Nie; Jin Zhu; Qingguo Yan; Hongzhang Chen; Haiyan Nan; Ying Guo
Journal:  SAGE Open Med Case Rep       Date:  2022-01-08

3.  Neck synovial sarcoma: case presentation.

Authors:  Konstantinos Sapalidis; Stiliani Laskou; Vasiliki Manaki; Vasiliki Magra; Stelian Pantea; Theodora Gkeka; Carmen Aurelia Mogoantă; Daniel Cristian Pîrvu; Isaak Kesisoglou
Journal:  Rom J Morphol Embryol       Date:  2021 Apr-Jun       Impact factor: 1.033

4.  Diagnostic Approach to Synovial Sarcoma of the Head and Neck Illustrated by Two Cases Arising in the Face and Oral Cavity.

Authors:  Primali Rukmal Jayasooriya; Lindumini Nayanahari Madawalagamage; Balapuwaduge Ranjit Rigorbert Nihal Mendis; Tommaso Lombardi
Journal:  Dermatopathology (Basel)       Date:  2016-03-22

5.  The First Ever Reported Case of Primary Synovial Sarcoma of Scalp.

Authors:  Biplab Mishra; Saurabh Singhal; Deepak Prakash Bhirud; Nitesh Kumar; Saumyaranjan Mallick
Journal:  Case Rep Surg       Date:  2016-06-29

6.  Synovial sarcoma of the maxillary sinus: an extremely rare case with excellent response to chemotherapy.

Authors:  Shin Saito; Hiroyuki Ozawa; Yuuichi Ikari; Nana Nakahara; Fumihiro Ito; Mariko Sekimizu; Junichi Fukada; Kaori Kameyama; Kaoru Ogawa
Journal:  Onco Targets Ther       Date:  2018-01-23       Impact factor: 4.147

7.  The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents.

Authors:  Monika Scheer; Christian Vokuhl; Sebastian Bauer; Jörg Fuchs; Steffan Loff; Beate Timmermann; Marc Münter; Anton George Henssen; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Ewa Koscielniak; Thomas Klingebiel
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-17       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.